No “Duty to Innovate” – California’s Highest Court Finds Gilead Sciences Not Negligent for Delaying Release of Allegedly Safer HIV Drug
Ari Feinstein & Rhett D. Ramsey
California court holds that drug manufacturers do not have a duty to commercialize a safer drug to replace a nondefective one.
FDA Approves First mRNA-Based Flu Vaccine, Highlighting Growing Patent Value in mRNA Platforms
Jason J. Jardine & Alistair J. McIntyre
The FDA’s approval of mFLUSIVA may indicate increased commercial and strategic value of mRNA vaccine patents.
PODCAST: Understanding AI and Patent Eligibility
Jarom D. Kesler & Bryan McWhorter
In this episode of Knobbe IP+, Knobbe Martens partners Jarom Kesler and Bryan McWhorter discuss the latest developments in AI and patent eligibility. Sharing insights for both fellow IP practitioners and inventors seeking to patent their latest innovations, Jarom and Bryan answer some of the most frequently asked questions surrounding the role of AI in the patent process: Can AI be listed as an inventor on a patent? What are the common pitfalls to avoid in the AI patenting process?
Subscribe for News and Updates